Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105300 · ClinicalTrials.gov registry record · Phase 3
Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00105300 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 300 participants.
The verdict
NCT00105300, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The goal of this study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease who have been initially treated with infliximab and either lost response or discontinued its use as a result of intolerance to the drug.
Interventions
- DRUG Adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2004-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105300
The ClinicalTrials.gov registry entry for NCT00105300 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Adalimumab is the first listed.
NCT00105300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00105300 about?
NCT00105300 is a clinical study titled "Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease". The goal of this study is to test whether adalimumab can induce clinical remission in subjects with active Crohn's disease who have been initially treated with infliximab and either lost response or discontinued its use as a result of intolerance to the drug.
What is the current status of trial NCT00105300?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2004-10.
What interventions are being tested in trial NCT00105300?
The interventions under investigation include: Adalimumab (DRUG).
Who is sponsoring clinical trial NCT00105300?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.